The global enteric disease testing market was valued at USD 3.81 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 2.7% from 2023 to 2030. The key drivers for this growth include technological advancements, increased government funding, and growing global demand for early diagnostic solutions. These factors are enhancing the applicability of enteric disease testing, contributing to the expansion of the market.

Technological advancements play a crucial role in accelerating the market's growth. One notable example is the development of gastrointestinal panel tests. These tests enable the rapid and simultaneous identification of multiple parasitic, bacterial, and viral nucleic acids in individuals who exhibit signs of gastroenteritis or infectious colitis. The tests, which are typically performed on stool or saliva samples, can identify up to 15 pathogens within just 6 hours, making them highly efficient. Additionally, these tests can be used to detect inherited food sensitivities or allergies caused by organisms such as Toxoplasma gondii and Entamoeba histolytica, which are known to affect the gastrointestinal system.

These advanced diagnostic tools have already been approved by regulatory bodies like the U.S. FDA, further boosting their credibility and adoption. For instance, the XTAG Gastrointestinal (GPP) test, approved in November 2019, is a multiplexed nucleic acid test designed to detect a range of viral, parasitic, and bacterial pathogens in stool samples. As clinical studies continue to advance and more diagnostic tests with higher accuracy and performance are developed, the market is expected to experience significant growth.

Gather more insights about the market drivers, restrains and growth of the Enteric Disease Testing market

Regional Insights

Europe

Europe held the dominant share of the global enteric disease testing market, accounting for 39.0% of the total revenue in 2022. The region's leadership can largely be attributed to Germany, which holds a significant portion of the market. Germany's large geriatric population plays a pivotal role in driving the demand for enteric disease testing. According to the United Nations population data, one in every 20 individuals in Germany is over the age of 80, and this proportion is expected to increase to one in every 6 people by 2050. Additionally, individuals over the age of 65 made up 22.4% of the total population in 2019, amounting to 90.4 million elderly people in Europe.

The aging population presents unique challenges, including an increased susceptibility to enteric diseases, due to the aging process and declining immunity in older adults. As these individuals face a higher risk of infection, the need for rapid diagnostic solutions like point-of-care diagnostic devices becomes crucial. These diagnostic devices allow for quicker detection and treatment, reducing the risks associated with delayed diagnosis. To meet this demand, major market players, such as Roche and Bio-Rad, are strengthening their presence in Germany, which is expected to further boost the market for enteric disease testing in Europe.

Asia Pacific

The Asia Pacific region is anticipated to grow at the fastest compound annual growth rate (CAGR) of 4.0% from 2023 to 2030. This growth is primarily fueled by increasing awareness about the importance of early testing and the rising incidence of enteric infections. Developing nations like China and India are expected to be key drivers of this growth due to their large populations, rapidly expanding healthcare sectors, and government efforts to increase access to diagnostic services.

In particular, Bangladesh reports the highest number of typhoid cases globally, with 252 cases per 100,000 people, highlighting the growing need for efficient enteric disease testing in the region. As the prevalence of these diseases rises, there is a significant demand for improved diagnostic tools and testing capabilities. The increasing awareness among the population about the benefits of early detection will likely contribute to the rapid growth of the market in Asia Pacific.

Brazil

Brazil presents significant opportunities for growth in the enteric disease testing market, supported by economic growth and political stability. Recent improvements in the Brazilian economy have led to better healthcare access, creating a favorable environment for the expansion of diagnostic services.

One key development in Brazil is the Unified Health System (SUS), which provides free healthcare services to all individuals, regardless of their financial status. The SUS system integrates public, private, and supplemental healthcare services, making healthcare more accessible to a larger portion of the population.

Additionally, government initiatives such as collaborations between the U.S. and Brazil in biomedical research are accelerating the research and development of diagnostic technologies for infectious diseases. These efforts are expected to further boost the demand for enteric disease testing in the country. However, challenges remain, as advanced diagnostics are currently more accessible in urban areas due to limited healthcare infrastructure in rural regions, which could potentially slow down overall market growth.

Browse through Grand View Research's  Medical Devices Industry Research Reports.

• The global medical simulation market size was estimated at USD 1.65 billion in 2024 and is expected to grow at a CAGR of 16.80% from 2025 to 2030. 

• The global intraoperative neuromonitoring market size was estimated at USD 3.49 billion in 2024 and is anticipated to grow at a CAGR of 5.97% over the forecast period.

Key Companies & Market Share Insights

The enteric disease testing market is highly competitive, with key players focusing on technological advancements and new product development to enhance their market position and offer cost-effective solutions. Several major players have made strategic moves to strengthen their presence in this market.

 

• BD (Becton, Dickinson and Company) launched an ultra-high-throughput molecular diagnostic platform in May 2022 for infectious diseases, specifically in the U.S. This fully automated system is designed to improve diagnostic accuracy and speed, catering to the growing demand for point-of-care testing.

• Thermo Fisher Scientific, Inc. made a significant move in February 2021 by acquiring Mesa Biotech, aiming to expand the reach of molecular diagnostics at the point of care. This acquisition aligns with the company's strategy to strengthen its position in the infectious disease diagnostic space.

 

Key Enteric Disease Testing Companies

Some of the major players contributing to the global enteric disease testing market include:

• Abbott

• BD (Becton, Dickinson and Company)

• Biomerica

• BIOMÉRIEUX

• Bio-Rad Laboratories, Inc.

• Cepheid

• Coris BioConcept

• DiaSorin S.p.A.

• Meridian Bioscience

• Quest Diagnostics Incorporated

Order a free sample PDF of the Enteric Disease Testing Market Intelligence Study, published by Grand View Research.